After naming 10 prescription drugs subject to direct government price negotiations, CMS released a series of questions directed at patients and other stakeholders as it prepared for direct price negotiations. Imbruvica was the only cancer drug in the ten selected drugs. CLL Society prepared responses related to patient experience, alternative treatments, prescribing information, impact and comparative effectiveness and more. Note the text is drafted as individual Q&As that had to be entered directly into the CMS portal